


Data Sheet

| | |
|---------------------------|--|
| Product Name: | SLLK, Control Peptide for TSP1 Inhibitor(TFA) |
| Cat. No.: | CS-0044304 |
| Molecular Formula: | C ₂₃ H ₄₂ F ₃ N ₅ O ₈ |
| Molecular Weight: | 573.60 |
| Target: | Others |
| Pathway: | Others |
| Solubility: | H ₂ O : 135 mg/mL (235.36 mM; Need ultrasonic) |



BIOLOGICAL ACTIVITY:

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for **LSKL**, which is a Thrombospondin (TSP-1) inhibitor. **In Vivo:** Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice^[1]. TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). MRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides^[2].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: ^[1]Mice^[1]

The i.p. injection of LSKL, SLLK, or saline began 2 weeks after uninephrectomy and continues thrice weekly for 15 weeks. For the low-dosage treatment regimen, each group of 20 mice receives 3 mg/kg body weight of peptide (LSKL or SLLK) per injection or saline (100 μL/10 g body weight per injection). For the high-dosage treatment regimen, Akita mice are given i.p. injections of LSKL or SLLK peptide at 30 mg/kg body weight per injection or saline (100 μL/10 g body weight per injection)^[1].

References:

[1]. Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178(6):2573-86.

[2]. Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98.

CAIndexNames:

SLLK, Control Peptide for TSP1 Inhibitor(TFA)

SMILES:

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA